A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters

The Coronavirus Disease 2019 (COVID-19) pandemic is unlikely to abate until sufficient herd immunity is built up by either natural infection or vaccination. We previously identified ten linear immunodominant sites on the SARS-CoV-2 spike protein of which four are located within the RBD. Therefore, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Bao-Zhong, Wang, Xiaolei, Yuan, Shuofeng, Li, Wenjun, Dou, Ying, Poon, Vincent Kwok-Man, Chan, Chris Chung-Sing, Cai, Jian-Piao, Chik, Kenn KaHeng, Tang, Kaiming, Chan, Chris Chun-Yiu, Hu, Ye-Fan, Hu, Jing-Chu, Badea, Smaranda Ruxandra, Gong, Hua-Rui, Lin, Xuansheng, Chu, Hin, Li, Xuechen, To, Kelvin Kai-Wang, Liu, Li, Chen, Zhiwei, Hung, Ivan Fan-Ngai, Yuen, Kwok Yung, Chan, Jasper Fuk-Woo, Huang, Jian-Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118541/
https://www.ncbi.nlm.nih.gov/pubmed/33890550
http://dx.doi.org/10.1080/22221751.2021.1921621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118541/
https://www.ncbi.nlm.nih.gov/pubmed/33890550
http://dx.doi.org/10.1080/22221751.2021.1921621

Ejemplares similares